How Genomate is paving the way for more precise, effective lung cancer treatments
Genomate Health shared a post on LinkedIn about a recent paper by Anna Dirner et al. published in ASCO, commenting:
“In 2024, an estimated 234,580 new cases of lung cancer will be diagnosed in the US, and sadly, 125,070 people will lose the battle with this devastating disease. With lung cancer remaining one of the most challenging cancers to treat, the need for innovative treatment approaches is more urgent than ever.
At Genomate Health, we are committed to transforming these statistics through AI-driven precision oncology. We are proud to share our latest research, published at American Society of Clinical Oncology (ASCO) 2024.
Our work focuses on harnessing the power of AI and comprehensive molecular profiling to provide personalized treatment options for lung cancer patients, ultimately enhancing treatment efficacy.
Read our full abstract here and discover how Genomate is paving the way for more precise, effective lung cancer treatments.”
“Real-world performance of the digital drug-assignment system for precision oncology in lung cancer”
Authors: Anna Dirner, Robert Doczi, Dora Kormos, Dora Lakatos, Marton Bolyacz, Dora Tihanyi, Akos Takacs, Akos Boldizsar, Maria Kocsis-Steinbach, Barbara Vodicska, Reka Szalkai-Denes, Edit Varkondi, Julia Deri, Dora Mathiasz, Istvan Valyi-Nagy, Richard Schwab, Maud Kamal, Christophe Le Tourneau, Laszlo Urban, Istvan Petak.
Source: Genomate Health/LinkedIn